The 14th Annual Meeting of Chinese American Pathologists Association

Saturday, March 12, 2:30 – 4:30 PM, 2016
Sheraton Hotel Metro Ballroom A, Seattle, WA
The primary mission of the CAPA is to improve educational opportunities and professional skills of practicing pathologists of Chinese ethnicity, by promoting communication, friendship and cultural exchange, and by advancing the science and practice of pathology and laboratory medicine.

http://www.capaht.org

CAPA Acknowledges the Following Sponsors for Their Support

Advanced Cell Diagnostics, Inc.
American Society of Clinical Pathology
BioGenex
Cell Marque
Dian Diagnostics
Foundation Medicine
Geisinger IHC Reference Lab
Gopath
Kingmed
Maixin
Motic
NovoDix, Inc.
Roche/Ventana
Roche Diagnostics China
Rosetta Genomics
Dear CAPA friends:

It was my great honor to serve as the Chinese American Pathologists Association (CAPA) President in 2015. It certainly was a great year for CAPA! Together, we have accomplished the goals that I announced at the last CAPA Annual Business Meeting in Boston. Congratulations and thanks to all CAPA members, especially those of you who have been actively involved in and contributed to this great pathology community! Because of your strong support, dedication and contributions, CAPA achieved many goals and reached many impressive new milestones in 2015, such as:

- Establishing functional CAPA Subcommittees;
- Hosting the first CAPA Diagnostic Pathology Course in New York City;
- Co-organizing the first CAPA-Beijing Diagnostic Pathology Course in Beijing;
- Participating in the Chinese Society of Pathology (CSP) 2015 Annual Meeting in Kunming;
- Participating in the 9th AP-IAP Meeting in Brisbane, Australia;
- Publishing quarterly CAPA eNewsletters;
- Refining the CAPA website and increasing the number of website visits;
- Authoring a special section of review articles based on the CAPA Diagnostic Pathology Course for the *Archives of Pathology and Laboratory Medicine*;
- Preparing for the first CAPA Companion Meeting at the 2016 CAP meeting;
- Recruiting many more members, including many lifetime members;
- Attracting more sponsors to make CAPA more financially stable and healthier than ever;
- Improving management of the CAPA pre-existing accounts and completing an auditing process;
- Creating two new CAPA awards - CAPA Honorary Award and CAPA Member of the Year Award.

For the complete annual report, please go to the CAPA website ([http://www.capaht.org/](http://www.capaht.org/)) or read the 4th issue of the CAPA eNewsletter.

In summary, the CAPA community is well-prepared and positioned for future growth. Again, I am honored to have had the opportunity to serve as its President in 2015! My professional life has been greatly enriched, inspired, and influenced by the many friends and colleagues I have met along the way, especially those with whom I have had close interactions during the last year. I am grateful to the CAPA Executive Committee, Subcommittee chairs and co-chairs, Subcommittee members, and all the members and volunteers who worked closely with me to accomplish these ambitious goals. Together, we did it! Once again, I sincerely appreciate all sponsors for their very generous support. Finally, I strongly encourage all of you to be volunteers and more actively involved in all CAPA activities, now and in the future, because this is OUR OWN pathology community! Now, Dr. Huamin Wang and the entire CAPA leadership team will take the CAPA to the next level. Together, we will build an even stronger CAPA!

Respectfully submitted,

Fan Lin, MD, PhD
CAPA President, 2015-2016
Welcome to the 14th Chinese American Pathologists Association (CAPA) Annual Meeting In Seattle!

Congratulations to the presidents-elect, Dr. Ping Tang!

It is my distinguished honor and privilege to be elected as the president of the Chinese American Pathologists Association (CAPA) for 2016-2017.

CAPA has become an internationally recognized organization within the pathology community, thanks to the strong leadership and strategic visions of our past presidents; dedication from our current and past executive committee members, subcommittee chairs, co-chairs and members; and strong support from our active members.

I would like to express my special thanks to Dr. Fan Lin for his strong leadership and to his leadership team and many active members for their hard work and outstanding contributions in the past year. We are having another historic and successful gathering in Seattle, because our members contributed their precious time and effort with the leadership of Dr. Fan Lin and his team. I would like to thank our sponsors for their generous support and professional partnerships with CAPA. I would like to thank and welcome all CAPA members as well as our distinguished friends in pathology from China to this meeting.

Strong and dedicated teamwork is the major force that has driven the CAPA forward at an unprecedented pace in recent years. Under the outstanding leadership of Dr. Fan Lin, we have achieved numerous milestones in CAPA’s history in the past year as listed in Dr. Lin’s CAPA Annual Report. As we move into the next year, I look forward to working with our leadership teams and active members to continue these great programs and to implement new programs, including the 1st CAPA Companion Meeting at 2016 CAP Annual Meeting, the CAPA Diagnostic Pathology Course in Houston, the CAPA-Beijing Pathology Symposium etc. We are also in the process of amending the CAPA bylaws; improving the CAPA web site; validating and organizing our membership databases; and updating CAPA member email list to better communication with our members.

Together as a team, we will make CAPA a stronger and better organization in the coming years!

Sincerely yours,

Huamin Wang, MD, PhD
Professor
Department of Pathology & Department of Translation Molecular Pathology
University of Texas M.D. Anderson Cancer Center, Houston, TX
CAPA President, 2016-2017
1:30 – 2:30 PM | Registration and Refreshments

2:30 – 3:00 PM | CAPA Business Meeting
- Opening remarks and CAPA Annual Report: Dr. Fan Lin, CAPA President, 2015-2016
- CAPA Finance Report: Dr. Zongming (Eric) Chen, CAPA Treasurer
- CAPA Membership Update: Dr. Lizhen Gui, Chair of Membership Subcommittee
- CAPA Bylaws Changes: Dr. Huamin Wang, CAPA President, 2016-2017

3:00 – 3:15 PM | Scientific Presentations by Meeting Platinum Sponsors
- Advanced Cell Diagnostics, Inc.
- Foundation Medicine
- NovoDix

3:15 – 4:00 PM | Presenting CAPA Awards
- CAPA Honorary Award: Presented by Dr. Fan Lin, CAPA President, 2015-2016
- CAPA/ACD Distinguished Pathologist Awards: Presented by Drs. Yuling Lou (ACD CEO) and Fan Lin
- CAPA/Zu-Hua Gao Service Award: Presented by Dr. Zu-Hua Gao, CAPA President 2012-2013
- CAPA Member of the Year Award: Presented by Dr. Fan Lin, CAPA President 2015-2016
- CAPA/Gopath Best Abstract Awards: Presented by Drs. Hanlin Wang and Zhenbin Lu
- CAPA/Motic Best Abstract Awards: Presented by Dr. Guoping Cai and Mr. Richard Yeung, Motic CEO
- CAPA Past Presidents Recognition Plaques: Presented by Dr. Chin-Lee Wu

4:00 – 4:15 PM | Remarks from CAP, USCAP and CSP Officials
- Dr. Richard Friedberg, CAP President
- Dr. David Kaminsky, USCAP EVP
- Dr. Xiu-Wu Bian, CSP President

4:15 – 4:30 PM | Looking Forward
- Dr. Huamin Wang, CAPA President 2016-2017

4:30 – 5:30 PM | Bus, Taxi, or Walking to China Harbor Restaurant
Free Buses (Shuttle Express) available at 5:00 PM at the front door of Sheraton Hotel.
China Harbor Restaurant [http://www.seattlechinaharbor.com; 2040 Westlake Avenue N., Seattle, WA 98109; (206) 286-1688]

5:30 – 10:00 PM | CAPA Annual Dinner Party and Karaoke
CAPA Awards

**CAPA Honorary Award**

**Philip T. Cagle, MD,** is the editor-in-chief of the Archives of Pathology & Laboratory Medicine, Director of Pulmonary Pathology at Houston Methodist Hospital and Professor of Pathology and Laboratory Medicine at Weill Cornell Medical College. Dr. Cagle received his MD degree from the University of Tennessee College of Medicine in Memphis in 1981. After completing his pathology residency at the Baylor College of Medicine in Houston, Texas, from 1981 to 1985, he completed a fellowship in pulmonary pathology at the University of British Columbia in Vancouver, Canada, from 1985 to 1987. In 1987, he joined the faculty at Baylor College of Medicine and joined the faculty at Houston Methodist Hospital and Weill Cornell Medical College in 2004. Dr. Cagle is Co-Chair and co-author of the CAP/IASLC/AMP Lung Cancer Predictive Biomarker Guidelines, Chair of the CAP Cancer Biomarker Reporting Committee and Advisor to several other CAP Committees. He is current Program Committee Chair and former President of the Pulmonary Pathology Society as well as Education Council Chair for the Texas Society of Pathologists. He is editor of 16 textbooks on pulmonary pathology, editor of 2 electronic books, series editor for 3 book series and author of 100 book chapters and 200 journal articles. Dr. Cagle is a recipient of the CAP Distinguished Patient Care Award, the CAP Pathologist of the Year Award (2013), the Alfred Soffer Research Award from the American College of Chest Physicians and the Texas Society of Pathologists John J. Andujar, MD Citation of Merit Award.

**CAPA/ACD Distinguished Pathologist Award**

**Hanlin L. Wang, MD, PhD,** is a Professor of Pathology, Chief of Gastrointestinal Pathology and Director of Gastrointestinal/Liver Pathology Fellowship Program at David Geffen School of Medicine, University of California at Los Angeles. Dr. Wang graduated from Hubei Medical College (now Wuhan University School of Medicine) and obtained his PhD degree in Biomedical Sciences from Mayo Clinic. He completed pathology residency training at University of Chicago followed by gastrointestinal/liver pathology fellowship training at the same institution with Dr. John Hart. Dr. Wang’s research interests have been medical and neoplastic gastrointestinal and hepatobiliary diseases, with a focus on biomarkers that may have diagnostic, therapeutic or prognostic significance. His publications include more than 130 research articles, 34 book chapters, and two books (co-editors). Dr. Wang is one of the earliest members of CAPA.

**Jinsong Liu, MD, PhD,** is a professor with tenure in the Department of Pathology at The University of Texas M. D. Anderson Cancer Center. He received his Ph.D. degree in Biochemistry from Case Western Reserve University in 1991 and completed his pathology residency and surgical pathology fellowship training at New York University School of Medicine from 1994 to 1999. He is certified by American Board of Anatomic Pathology. He joined the faculty in the Department of Pathology at The University of Texas M. D. Anderson Cancer in 1999 as an Assistant Professor and was promoted to Associate Professor in 2004 and professor in 2009 with tenure. Dr. Liu is an internationally recognized for his expertise in diagnosis of gynecologic malignancy and research achievements in ovarian cancer. His research has focused on inflammation, tumor microenvironment, cancer stem cells, and prognostic markers for ovarian cancer. Dr. Liu’s research has been continuously funded by more than 30 grants from different funding agencies in the past 15 years. Dr. Liu has been an editorial member of several reputable journals. Dr. Liu has co-authored 200 peer reviewed original publications and 22 reviews. Dr. Liu has been a member of CAPA since her establishment in 2003 and former president of CAPA (2013-2014).
CAPA Awards (Continued)

CAPA/Zu-Hua Gao Service Award

**Marilyn M. Bui**, MD, PhD, is Senior Member of the Anatomic Pathology Department, the Scientific Director of Analytic Microscopy Core, and the Program Leader of Anatomic Pathology Education at Moffitt Cancer Center. She is also a Professor and Director of Cytopathology Fellowship at the University of South Florida Morsani College of Medicine. She has expertise in sarcoma pathology, cytopathology, and digital pathology. In CAPA, she served as a member of the Executive Committee and chaired the Education Committee for the past two years. Recently Dr. Bui is recognized by *The Pathologist* magazine as one of its inaugural Top 100 Power List, which celebrates the exceptional achievements of those who have really had an impact on the field of pathology; and to highlight the truly groundbreaking work of laboratory medicine and its intrinsic role in patient care and the molecular revolution.

**CAPA Member of the Year Award**

**Zongming (Eric) Chen**
MD, PhD
CAPA Treasurer for 2015-2018

**Ruoqing Huang**
MD, PhD
A Strong CAPA Supporter and Advocate

**Fan Chen**
MD, PhD
Co-chair for CAPA Membership and Publication Subcommittees 2015-2017

**Huihong Xu**
MD, PhD
Key Member of CAPA Finance Subcommittee 2015-2017

**Lizhen Gui**
MD, PhD
Chair for CAPA Membership Subcommittee 2015-2017

**Lanjing Zhang**
MD, MS
Co-chair for CAPA Education Subcommittee 2015-2017
**CAPA Awards (Continued)**

**CAPA/Gopath Best Abstract Award**

**First Prize:** Wei Wang, MD, PhD, UT MD Anderson Cancer Center. Risk stratification of additional chromosomal changes in chronic myelogenous leukemia in era of tyrosine kinase inhibitor therapy

**Second Prize:** Hongyan Dai, MD, PhD, University of Kansas. miR-139 in breast cancer tumors and serum a surrogate marker for tumor aggression

**Second Prize:** Qingqing Liu, MD, PhD, University of Massachusetts. Hemizygous deletion of RB1 gene in chromophobe renal cell carcinoma and its potential role in distinguishing chromophobe renal cell carcinoma from renal oncocytoma

**Third Prize:** Jinhua Piao, MD, St. Louis University. Vasodilator stimulated phosphoprotein (VASP) immunoreactivity is associated with lymphovascular invasion of colorectal adenocarcinoma (CRC) leading to liver and lymph node metastases

**Third Prize:** Wendi Zhou, MD, PhD, University of California at Los Angeles. Diagnostic utility of clusterin immunostaining in differentiating hepatocellular carcinoma from tumors of other origins

**Third Prize:** Bing Ren, MD, PhD, University of Pittsburgh. Programmed death ligand-1 (PD-L1) expression in mismatch repair deficient gastric tumors and gastric tumors positive for Epstein-Barr virus

---

**CAPA/Motic Best Abstract Award**

**First Place Prize**
A new variant of phosphaturic mesenchymal tumor exclusively involving alveolar bone: a clinicopathological analysis of 17 cases

**Huanwen Wu**¹, Marilyn M. Bui², Yunxia Meng¹, Lian Zhou³, Xinxin Mao¹, Zhiyong Liang¹, Dingrong Zhong¹

¹ Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China
² Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, FL, USA
³ Department of Stomatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China

**Second Place Prize**
Zic2 promotes tumor growth and metastasis via PAK4 in hepatocellular carcinoma

**Shi-Xun Lu**¹,², Chris Zhiyi Zhang¹,², Rong-Zhen Luo¹,², Li-Li Liu¹,², Jia Fu¹,², Jing-Ping Yun¹,²

¹ Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
² Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
**Second Place Prize (Continued)**

**MicroRNA expression of Peripheral T and NK cell lymphomas in one hospital**

**Lin Feng**\(^1\), Linshu Zeng\(^2\), Ling Shan\(^2\), Yanning Gao\(^1\), Yu Liu\(^1\), Ning Lu\(^2\), Shujun Cheng\(^1\), Xiaoli Feng\(^2\)

\(^1\) State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, Cancer Hospital and Institute, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China

\(^2\) Department of Pathology, Cancer Hospital and Institute, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China

**Third Place Prize**

**Parameters associated with recurrence of pT1N0 esophageal squamous cell carcinoma after radical esophagectomy**

**Liyan Xue**\(^1\)^§, Xiumin Qin\(^2\), Yong Liu\(^2\), Jun Liang\(^3\), Feiyue Feng\(^4\), Hua Lin\(^5\), Zhouguang Hu\(^i\), Yueming Zhang\(^2\), Xuemin Xue\(^1\), Liqun Ren\(^1\)^\(^6\), Shuangmei Zou\(^1\), Xiuyun Liu\(^1\), Yanling Yuan\(^1\), Jianming Ying\(^1\), Luhua Wang\(^3\), Sanford M. Dawsey\(^7\), Guiqi Wang\(^2\), Ning Lu\(^1\)

\(^1\) Department of Pathology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

\(^2\) Department of Endoscopy, Cancer Institute & Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

\(^3\) Department of Radiation Oncology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

\(^4\) Department of Thoracic Surgery, Cancer Institute & Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

\(^5\) Department of Medical Record, Cancer Institute & Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

\(^6\) Department of Pathology, Chengde Medical College, Chengde, China

\(^7\) Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA

**High Risk HPV Testing and Report Rate: Result from the Largest CAP Certified Independent Laboratory in China**

**Baowen Zheng**\(^1\), Zaibo Li\(^2\), Zhenyu Zeng\(^1\), Congde Chen\(^1\), Ja You\(^1\), Lingyun Tan\(^1\), Chengquan Zhao\(^3\)

\(^1\) Guangzhou Kingmed Diagnostics, Guangzhou, Guangdong

\(^2\) Department of Pathology, Ohio State University Medical Center, Columbus, Ohio

\(^3\) Department of Pathology, Magee-Women's Hospital of UPMC, Pittsburgh, PA

**Endocervical curettage should be performed in women older than 35 with cytological high-grade squamous intraepithelial lesions or carcinomas regardless of colposcopy impression**

**Yan Song**\(^1\), Yu-Qian Zhao\(^2\), Ling Li\(^1\), Qin-Jin Pan\(^1\), Wen-Hua Zhang\(^3\), Fang-Hui Zhao\(^i\), Wen Chen\(^2\), Xun Zhang\(^1\), You-Lin Qiao\(^2\)

\(^1\) Department of Pathology

\(^2\) Department of Epidemiology

\(^3\) Department of Gynecology

Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
CAPA Past Presidents Recognition

Chin-Lee Wu (2002-2005)
Ximeng Yang (2006)
Bin Yang (2007)
Shu-Yuan Xiao (2008)
Shuan Li (2009)
Ming Zhou (2010)
Steven Shen (2011)
Zu-Hua Gao (2012)
Jinsong Liu (2013)
Qihui (Jim) Zhai (2014)
Fan Lin (2015)

CAPA Executive Committee

Fan Lin (President 2015-2016)
Huamin Wang (President 2016-2017)
Ping Tang (President-elect 2017-2018)
Qihui (Jim) Zhai (Past President 2014-2015)
Zongming (Eric) Chen (Treasurer)
Marilyn Bui
Guoping Cai
Lizhen Gui
Chen Liu
Huan-You Wang
Lanjing Zhang
Jun Zhang

CAPA Publication Subcommittee/Editing Team

Huan-You Wang
Jun Zhang
Fan Chen
Jie Song
Zenggang Pan

Design for Brochure
Fan Chen (2016)
Huhiui Ye (2015)
Zenggang Pan (2015)

Website Master
Jie Song

Design for eNewsletter
Fan Chen
CAPA Lifetime Members

Bu, Lihong  
Cai, Jianping  
Chen, Baorong  
Chen, Fan  
Chen, Fayu (Mark)  
Chen, Helen  
Chen, Longwen  
Chen, Qianghua  
Cheng, Liang  
Cheng, Lirong  
Fan, Rong  
Gui, Lizhen  
Hu, Huankai  
Huang, Juan  
Jiang, Ming  
Jiang, Yuying  
Lee, Peng  
Li, Hong Catherine  
Li, Shuan  
Liang, Mei  
Liang, Songlin  
Lin, Fan  
Lin, Jingmei  
Liu, Haiyan  
Liu, James  
Liu, Jinsong  
Liu, Wendy  
Liu, Wenhua  
Luo, Frank  
Ma, Xiaoling  
Pei, Zhiheng  
Pu, Robert  
Qian, Xiaohua  
Shen, Steven  
Shen, Youjun  
Sun, Wei  
Tan, Dongfeng  
Tang, Daniel  
Tang, Ping  
Tang, Wozhan  
Wang, Beverly  
Wang, Hanlin  
Wang, Li (Larry)  
Wu, Chin-Lee  
Xiao, Shu-Yuan  
Xie, Silvia Xiuyan  
Xin, Wei  
Xu, Huihong  
Xu, Xiaomeng  
Yang, Bin  
Yang, Hongyu  
Yang, Ximing  
Ye, Huohui  
Yin, Hong (Julie)  
Yu, Hongbo  
Yu, Limin  
Zhai, Qihui (Jim)  
Zhang, David  
Zhang, Jun  
Zhang, Lanjing  
Zhang, Xiaohong  
Zhao, Chengquan  
Zhao, Xiaohui  
Zhao, Song Qing  
Zheng, Wenxin  
Zhou, Chen  
Zhou, Zhongren  
Zu, Youli

CAPA Senior Advisory Council (SAC) (Alphabetical order)

Longwen Chen, MD, PhD  
Mayo Clinic Arizona  
Fang Fan, MD, PhD  
University of Kansas Medical Center  
Zu-hua Gao, MD, PhD, FRCP  
McGill University Health Center  
Yun Gong, MD  
UT MD Anderson Cancer Center  
Jiaoti Huang, MD, PhD  
UCLA  
Qin Huang, MD, PhD  
Harvard Medical School, VA Boston Healthcare System  
Pei Hui, MD, PhD  
Yale University School of Medicine  
Maomi Li, MD, PhD  
Integrated Oncology (LabCorp Specialty Testing Group)  
Shuan C. Li, MD  
Orlando Health  
Fan Lin, MD, PhD  
Geisinger Medical Center  
Jinsong Liu, MD, PhD  
UT MD Anderson Cancer Center  
Wendy Liu, MD, PhD  
University Hospitals Case Medical Center  
Danielle Lu, MD  
Huntington Memorial Hospital, Pasadena, CA  
Steven Shen, MD, PhD  
Houston Methodist Hospital  
Weill Medical College of Cornell University  
Ping Tang, MD, PhD  
University of Rochester Medical Center  
Beverly Wang, MD  
UC Irvine Medical Center  
Hanlin Wang, MD, PhD  
UCLA  
Jun Wang, M.D.  
Loma Linda University Medical Center  
Chin-Lee Wu, MD, PhD  
Massachusetts General Hospital; Harvard Medical School  
Shu-Yuan Xiao, M.D.  
University of Chicago  
Wei Xin, MD, PhD  
University Hospital Case Medical center  
Haodong Xu, MD, PhD  
UCLA  
Bin Yang, MD, PhD  
Cleveland Clinic  
Ximing J. Yang, MD, PhD  
Northwestern University  
Qihui (Jim) Zhai, MD  
Mayo Clinic  
Lanjing Zhang, MD, MS  
University Medical Center of Princeton at Plainsboro; Rutgers University  
Jun Zhang, MD  
Mayo Clinic  
Paul J. Zhang, MD  
Hospital of the University of Pennsylvania, Perelman School of Medicine  
Chengquan Zhao, MD  
Magee-Womens Hospital University of Pittsburgh  
Wenxin Zheng, MD  
University of Arizona College of Medicine  
Chen Zhou, MD, PhD  
University of British Columbia, Vancouver, Canada  
Ming Zhou, MD, PhD  
New York University Medical Center, Tisch Hospital  
Youli Zu, MD, PhD  
Houston Methodist Hospital, Weill Medical College of Cornell University
Stains are a good thing...

*Quality* stains are our thing

Please stop by and see Geisinger IHC at the USCAP 2016 Annual Meeting in Seattle from March 14 – 16 at booth #538.

geisingerihc.com

**10 MINUTE INTRAOPERATIVE DIRECT IHC**

**Available Products:**
- *ihcDirect AE1/AE3*
- *ihcDirect Mart-1*
- *ihcDirect CK8/18*
- *ihcDirect Synaptophysin*
- *ihcDirect Herceptin*

**Time In Minute** | **Procedure**
--- | ---
0.5 | Fixation
0.1 | Wash in PBS
0 | No Blocking
5 | PolyHRP-ANTIBODY
0.1 | Wash in Water
1 | DAB
0.1 | Wash in Water
2-3 | Counter Staining + dehydration + Coverslipping

**9-10** | **Total Time**
Maixin provides comprehensive range of solutions for immunohistochemistry
Game Changer

Integrated eFISHiency System

- FISH Probes
- Detection Systems
- Smart Automation
  Hands-On Time < 30 min.
  Up to 10 protocols per run

For Clinical Research & Tumour Analysis:
- Cancer of Unknown Primary
- Undifferentiated Tumors
- Cancer Staging

Xmatrix NANO

miRNA In Situ - Dawn of a New Era

Xmatrix ELITE INFINITY and NANO
miRNA-ISH Automation
# Rare for you but not for Foundation Medicine

<table>
<thead>
<tr>
<th>RARE/UNCOMMON SUBTYPE</th>
<th>PERTINENT TUMOR DRIVER</th>
<th>FDA APPROVED TARGETED THERAPIES</th>
<th>FDA APPROVED THERAPIES IN ANOTHER TUMOR TYPE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-Serous Ovarian Cancers, e.g. Ovarian Clear cell</td>
<td>BRCA1/2, ERBB2, FGFR1/2/3, AKT1/2, PALB2</td>
<td>Olaparib</td>
<td>Trastuzumab, Pembrolizumab, Parpab, Ponazurib, Temsirolimus, Everolimus, Olaparib and others</td>
</tr>
<tr>
<td>Pancreatobiliary Cancers:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Cholangiocarcinoma</td>
<td>IOH1/2, ERBB2, FGFR2, BRAF, PTEN, BRCA1/2, ERBB2, BRAF, ERBB2</td>
<td></td>
<td>Anazoxine, Decabine, Trastuzumab, Pembrolizumab, Alzantib, Panpab, Dabrafenib, Trametinib, Vemurafenib, Everolimus, Trastuzumab, Pembrolizumab</td>
</tr>
<tr>
<td>- Pancreas</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Gallbladder</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uncommon subtypes of breast cancer</td>
<td>CCND1, BRCA1/2, ERBB2, ESRF, P53R1, NFI, STK11, AKT1/2, PTEN</td>
<td>Patiokilb</td>
<td>Olaparib, Astatib, Ceru Imab, Erlikinib, Lapatinib, Pembrolizumab, Trastuzumab, Everolimus, Temsirolimus, Olaparib</td>
</tr>
<tr>
<td>Salivary Gland</td>
<td>ERBB2, ESRF, PTEN, BRCA1/2, BRAF</td>
<td></td>
<td>Trastuzumab, Pembrolizumab, Cetuximab, Lapatinib, Temsirolimus, Everolimus, Olaparib, Trametinib, Dabrafenib</td>
</tr>
</tbody>
</table>

Comprehensive genomic profiling using FoundationOne has been performed on > 16,000 uncommon tumor cases. Learn more at: USCAP Annual Meeting Booth #541
No antibody. No problem.

Breakthrough multiplex RNA *in situ* hybridization for any gene with RNAscope® technology.

Because up to 76% of protein-coding genes have no reliable antibody for immunohistochemistry (IHC), your research often comes to a screeching halt while you wait for a new antibody to be developed. With rapid probe design and universal assay workflows for any gene, RNAscope® technology frees you from the hassles of antibody screening, saving you precious time and effort, while driving publication quality data.

Learn more about RNAscope® Technology at [www.acdbio.com](http://www.acdbio.com)

PD1 detection in lung cancer sample using RNAscope® 2.5 HD Reagent Kit-RED